Compare DRD & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | CPRX |
|---|---|---|
| Founded | 1895 | 2002 |
| Country | South Africa | United States |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | N/A | 2006 |
| Metric | DRD | CPRX |
|---|---|---|
| Price | $26.02 | $22.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $32.63 | ★ $35.00 |
| AVG Volume (30 Days) | 310.5K | ★ 1.0M |
| Earning Date | 08-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | N/A | ★ 1.68 |
| Revenue | N/A | ★ $119,072,803.00 |
| Revenue This Year | $34.35 | $8.00 |
| Revenue Next Year | $24.62 | $9.77 |
| P/E Ratio | $15.32 | ★ $13.28 |
| Revenue Growth | N/A | ★ 16.39 |
| 52 Week Low | $13.08 | $19.05 |
| 52 Week High | $39.37 | $26.56 |
| Indicator | DRD | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 38.69 |
| Support Level | $23.26 | $22.25 |
| Resistance Level | $30.91 | $24.94 |
| Average True Range (ATR) | 1.22 | 0.69 |
| MACD | -0.91 | -0.21 |
| Stochastic Oscillator | 3.35 | 12.84 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.